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Background
• Opioids are the most common class of
medications prescribed in the hospital, and the
second most common associated with serious
adverse events.1
• There is substantial clinical concern for the
morbidity and mortality associated with
respiratory compromise secondary to opioid
administration, particularly in unmonitored
patients or those with concurrent risk factors.
• The Joint Commission’s Sentinel Event database
from 2004-2011 reports improper monitoring to
be a leading cause of opioid related adverse
events.2
• The Anesthesia Patient Safety Foundation
(APSF) recommended that hospitalized patients
who are receiving opioids for post-operative pain
control should be monitored with continuous
pulse oximetry as well as continuous
capnography if supplemental oxygen is needed
to maintain adequate oxygen saturation.3

Problem Statement
To reduce avoidable harm from opioid induced
ventilatory impairment, Lehigh Valley Health Network
(LVHN) designed an Enhanced Respiratory
Monitoring (ERM) Pathway to improve the detection
of respiratory compromise using continuous
capnography in hospitalized patients receiving
opioids.

Methods
• Before and after evaluation of the impact of the
ERM Pathway on respiratory related adverse
events rates for patients receiving opioids.
• ERM project team defined cohorts of patients
and identified which would receive monitoring
with continuous capnography.

Sub-Cohort 1: Post-operative patients with obesity or sleep apnea
Will have capnography ordered
Sub-Cohort 2: Post-operative patients without obesity or sleep apnea
Will have capnography ordered for patients who receive oxygen
supplementation
Sub-Cohort 3: Non post-operative patients with sleep apnea or
obesity
Will have capnography ordered
Sub-Cohort 4: Non post-operative patients without sleep apnea or
obesity.
Will not receive capnography

• Clinical data tracked in the ERM analytics portal
• Adverse events, ICU transfers and Code Blues,
recorded as adverse event rate per 1000 patient
visits
• Goal was set to decrease the baseline rate from
22.3 (based on clinical outcomes from fiscal
years 2017 and 2018) to 17.8 (a 20% reduction
of baseline value)
• Program went live January 29, 2019

Results

Conclusions

• Post Intervention data is from the time period
March 2019-December 2019.
• The data was sorted to include both Muhlenberg
and Cedar Crest, across sub-cohorts 1-3,
specifically for patients meeting the requirements
for needing capnography.
• Sub-cohort 4 did not qualify for capnography, and
patients in sub-cohort 2 who did not require
supplemental oxygen did not qualify for
capnography and thus were also sorted out
• From March to December 2019 there were a total
of 4876 patient encounters that were in subcohorts 1-3 requiring capnography.
• The distribution of patient encounters, and
respective adverse events per sub-cohort are
detailed in Table 1.
• There were a total of 108 adverse events, 102 of
which were ICU transfers and 6 code blues
• The average adverse event rate, postintervention was 23.3, and therefore not reaching
the intended target.
• As seen in Table 2, sub-cohort 1 had an adverse
event rate increase from 18.4 pre-intervention to
20.1 post. Sub-cohort 2 had an increase in post
intervention adverse event rates, from 13 to 19.6.
However, sub-cohort 3 had a decrease in
adverse event rates post intervention, decreasing
from 28.5 to 24.8.

• The overall adverse event rates per 1000 patient
encounters increased from the baseline rate,
22.3 to 23.3, thus not reaching the target goal.
• Reasons for this increase may include:
– improved patient monitoring has allowed for
identification of respiratory compromise in
previously undetected cases
– capnography allowing for a possible earlier
detection in respiratory compromise, earlier
initiation of ICU transfer, therefore now
occurring in the time frame used to log
adverse events.

• To address limitations, future steps may include
better filtering the data collected in the analytics
portal. For example, chart review to ensure that
the adverse events are secondary to opioid use
or ensuring that the measured adverse events
have validated vitals from capnography.
• Relation to SELECT competencies:
– The project explored health systems/quality
improvement by demonstrating an
understanding of how LVHN was able to
develop the ERM pathway and analyze the
intervention.

Implications

Table 1: Adverse Events, Post-Intervention MarchDecember 2019
Sub-Cohort 1:
Post-operative patients with
obesity or sleep apnea
Sub-Cohort 2:
Post-operative patients without
obesity or sleep apnea, qualifying
for capnography
Sub-Cohort 3:
Non post-operative patients with
sleep apnea or obesity
Total

Total Patient
Encounters

ICU
Transfers Code Blues

1147

21

2

1431

27

1

2298
4876

54
102

3
6

• Although the metrics in the analytics portal
suggest that the intervention did not achieve the
desired goal, there is agreement from core team
members that the implementation of the pathway
has been an improvement in patient safety.
• Since implementation of the pathway, there has
been no case of avoidable respiratory
compromise due to opioid administration.
• Future implications of the project include
expanding the pathway to other LVHN sites as
well as additional patient populations such as
maternal care and medically complex patients
receiving sedation.

Table 2: Adverse Event rate per 1000 patient encounters

Sub-Cohort 1:
Post-operative
patients with
obesity or sleep
apnea
Sub-Cohort 2:
Post-operative
patients
without obesity
or sleep apnea,
qualifying for
capnography
Sub-Cohort 3:
Non postoperative
patients with
sleep apnea or
obesity
Total

PostPost-Intervention
PostIntervention, Intervention,
Pre-Intervention (March 2019December 2019) ICU Transfer Code Blue
Baseline,
adverse
total adverse total adverse event
adverse
event rate
rate
event rate
event rate
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